Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
Bioorganic & Medicinal Chemistry Letters
|
December 20, 2011
Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes
Jon M Sutton, David E Clark, Stephen J Dunsdon, et al.
Journal of Medicinal Chemistry
|
January 31, 2013
A novel class of oral direct renin inhibitors: highly potent 3,5-disubstituted piperidines bearing a tricyclic p3-p1 pharmacophore
Nils Ostermann, Simon Ruedisser, Claus Ehrhardt, et al.
Journal of Medicinal Chemistry
|
June 17, 2017
Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo
Edwige Lorthiois, Karen Anderson, Anna Vulpetti, et al.
Nature Communications
|
December 2, 2025
Identification and characterization of binders to a cryptic and functional pocket in KRAS
Kim S Beyer, Jessica Klein, Stéphanie Katz, et al.
Nature Chemical Biology
|
November 4, 2016
Small-molecule factor D inhibitors targeting the alternative complement pathway
Jürgen Maibaum, Sha-Mei Liao, Anna Vulpetti, et al.
Journal of Medicinal Chemistry
|
July 10, 2025
Promise and Challenge of β-Lactone Electrophiles to Target Aspartate 12 of Mutant KRAS<sup>G12D</sup>
Balázs Budai, Andrea Vaupel, Callum J Dickson, et al.
Journal of Medicinal Chemistry
|
November 18, 2022
JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS<sup>G12C</sup> for the Treatment of Solid Tumors
Edwige Lorthiois, Marc Gerspacher, Kim S Beyer, et al.
Journal of Medicinal Chemistry
|
September 15, 2020
Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4
Robin A Fairhurst, Thomas Knoepfel, Nicole Buschmann, et al.
Cancer Discovery
|
April 11, 2022
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
Andreas Weiss, Edwige Lorthiois, Louise Barys, et al.
Journal of Medicinal Chemistry
|
March 31, 2025
Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of Ras
Charles W Parry, Francesca Pellicano, Alexander W Schüttelkopf, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
Bioorganic & Medicinal Chemistry Letters
|
December 20, 2011
Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes
Jon M Sutton, David E Clark, Stephen J Dunsdon, et al.
Journal of Medicinal Chemistry
|
January 31, 2013
A novel class of oral direct renin inhibitors: highly potent 3,5-disubstituted piperidines bearing a tricyclic p3-p1 pharmacophore
Nils Ostermann, Simon Ruedisser, Claus Ehrhardt, et al.
Journal of Medicinal Chemistry
|
June 17, 2017
Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo
Edwige Lorthiois, Karen Anderson, Anna Vulpetti, et al.
Nature Communications
|
December 2, 2025
Identification and characterization of binders to a cryptic and functional pocket in KRAS
Kim S Beyer, Jessica Klein, Stéphanie Katz, et al.
Nature Chemical Biology
|
November 4, 2016
Small-molecule factor D inhibitors targeting the alternative complement pathway
Jürgen Maibaum, Sha-Mei Liao, Anna Vulpetti, et al.
Journal of Medicinal Chemistry
|
July 10, 2025
Promise and Challenge of β-Lactone Electrophiles to Target Aspartate 12 of Mutant KRAS<sup>G12D</sup>
Balázs Budai, Andrea Vaupel, Callum J Dickson, et al.
Journal of Medicinal Chemistry
|
November 18, 2022
JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS<sup>G12C</sup> for the Treatment of Solid Tumors
Edwige Lorthiois, Marc Gerspacher, Kim S Beyer, et al.
Journal of Medicinal Chemistry
|
September 15, 2020
Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4
Robin A Fairhurst, Thomas Knoepfel, Nicole Buschmann, et al.
Cancer Discovery
|
April 11, 2022
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
Andreas Weiss, Edwige Lorthiois, Louise Barys, et al.
Journal of Medicinal Chemistry
|
March 31, 2025
Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of Ras
Charles W Parry, Francesca Pellicano, Alexander W Schüttelkopf, et al.
Page
of 4